# Nivolumab in Combination With Ipilimumab (Part 1); Nivolumab Plus Ipilimumab in Combination With Chemotherapy (Part 2) as First Line Therapy in Stage IV Non-Small Cell Lung Cancer

> **NCT02659059** · PHASE2 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 324 (actual)

## Conditions studied

- Non-Small-Cell Lung Cancer

## Interventions

- **BIOLOGICAL:** Nivolumab
- **BIOLOGICAL:** Ipilimumab
- **DRUG:** Platinum Doublet Chemotherapy

## Key facts

- **NCT ID:** NCT02659059
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-02-15
- **Primary completion:** 2018-06-22
- **Final completion:** 2022-03-07
- **Target enrollment:** 324 (ACTUAL)
- **Last updated:** 2023-04-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02659059

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02659059, "Nivolumab in Combination With Ipilimumab (Part 1); Nivolumab Plus Ipilimumab in Combination With Chemotherapy (Part 2) as First Line Therapy in Stage IV Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02659059. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*